GLP1-s is a glucagon-like peptide-1 (GLP-1) receptor agonist initially developed for managing type 2 diabetes. It has gained FDA approval for chronic weight management in adults with obesity or overweight conditions. By mimicking the GLP-1 hormone, semaglutide enhances insulin secretion, suppresses glucagon release, and slows gastric emptying, leading to reduced appetite and increased feelings of fullness. Clinical studies have demonstrated significant weight loss in individuals using semaglutide alongside a healthy diet and exercise regimen.
GLP1-s mimics the GLP-1 hormone, enhancing insulin secretion, suppressing glucagon release, and slowing gastric emptying. These actions lead to reduced appetite and increased feelings of fullness, contributing to weight loss.
Common side effects include nausea, vomiting, diarrhea, abdominal pain, and constipation. These gastrointestinal symptoms often diminish over time as the body adjusts to the medication.
GLP1-s is suitable for adults with a body mass index (BMI) of 30 or higher, or those with a BMI of 27 or higher accompanied by weight-related health conditions such as hypertension or type 2 diabetes. A healthcare provider can assess individual suitability
Weight loss effects can begin within the first few weeks of treatment, with significant results typically observed after 20 weeks of use. Long-term use, in conjunction with a healthy diet and exercise, is recommended for sustained weight loss.